Literature DB >> 19041717

Modelling placebo response in depression trials using a longitudinal model with informative dropout.

Roberto Gomeni1, Agnes Lavergne, Emilio Merlo-Pich.   

Abstract

Dropouts are common events in longitudinal studies in depression. Ignoring missing information may lead to biased and inconsistent assessment of study results. A non-linear model was recently developed to describe the time-course of HAMD-17 clinical score in the placebo arms of antidepressant clinical trials. In this paper we complemented this model by introducing an informative dropout component to jointly estimate HAMD-17 time-course and dropout mechanism. The aims of this work were to: (a) characterise typical placebo response in depression trials in presence of dropouts, (b) explore which dropout mechanism better describe the time-varying probability of a subject to dropout from the trial, and (c) define a framework for the development of clinical trial simulation in depression. A meta-analytic approach was used on placebo data collected in 6 clinical trials including 695 subjects suffering from Major Depressive Disorders. Alternative hypotheses for "missingness" were evaluated using different hazard models. The "Missing Not At Random" performed statistically (p<0.01) better than "Missing At Random", that in turn performed better (p<0.01) than "Missing Completely At Random" model. This finding provided new insights on the validity of the analyses currently used in many longitudinal clinical trials to support the registration of a new medicinal product.

Entities:  

Mesh:

Year:  2008        PMID: 19041717     DOI: 10.1016/j.ejps.2008.10.025

Source DB:  PubMed          Journal:  Eur J Pharm Sci        ISSN: 0928-0987            Impact factor:   4.384


  15 in total

1.  Trajectories of depression severity in clinical trials of duloxetine: insights into antidepressant and placebo responses.

Authors:  Ralitza Gueorguieva; Craig Mallinckrodt; John H Krystal
Journal:  Arch Gen Psychiatry       Date:  2011-12

2.  Structural models describing placebo treatment effects in schizophrenia and other neuropsychiatric disorders.

Authors:  Venkatesh Pilla Reddy; Magdalena Kozielska; Martin Johnson; An Vermeulen; Rik de Greef; Jing Liu; Geny M M Groothuis; Meindert Danhof; Johannes H Proost
Journal:  Clin Pharmacokinet       Date:  2011-07       Impact factor: 6.447

3.  Performance of nonlinear mixed effects models in the presence of informative dropout.

Authors:  Marcus A Björnsson; Lena E Friberg; Ulrika S H Simonsson
Journal:  AAPS J       Date:  2014-11-25       Impact factor: 4.009

4.  Exposure-response analysis after subcutaneous administration of RBP-7000, a once-a-month long-acting Atrigel formulation of risperidone.

Authors:  Vijay Ivaturi; Mathangi Gopalakrishnan; Jogarao V S Gobburu; Weiyan Zhang; Yongzhen Liu; Christian Heidbreder; Celine M Laffont
Journal:  Br J Clin Pharmacol       Date:  2017-03-31       Impact factor: 4.335

5.  Modelling and simulation of the Positive and Negative Syndrome Scale (PANSS) time course and dropout hazard in placebo arms of schizophrenia clinical trials.

Authors:  Venkatesh Pilla Reddy; Magdalena Kozielska; Martin Johnson; Ahmed Abbas Suleiman; An Vermeulen; Jing Liu; Rik de Greef; Geny M M Groothuis; Meindert Danhof; Johannes H Proost
Journal:  Clin Pharmacokinet       Date:  2012-04-01       Impact factor: 6.447

Review 6.  Modelling and simulation of placebo effect: application to drug development in schizophrenia.

Authors:  Venkatesh Pilla Reddy; Magdalena Kozielska; Rik de Greef; An Vermeulen; Johannes H Proost
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-01-12       Impact factor: 2.745

7.  Handling missing data in a duloxetine population pharmacokinetic/pharmacodynamic model - imputation methods and selection models.

Authors:  Eunice Yuen; Ivelina Gueorguieva; Leon Aarons
Journal:  Pharm Res       Date:  2014-05-03       Impact factor: 4.200

8.  General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry.

Authors:  Thomas C Baghai; Pierre Blier; David S Baldwin; Michael Bauer; Guy M Goodwin; Kostas N Fountoulakis; Siegfried Kasper; Brian E Leonard; Ulrik F Malt; Dan Stein; Marcio Versiani; Hans-Jürgen Möller
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2011-11       Impact factor: 5.270

9.  Development of a placebo effect model combined with a dropout model for bipolar disorder.

Authors:  Wan Sun; Thomas P Laughren; Hao Zhu; Guenther Hochhaus; Yaning Wang
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-03-02       Impact factor: 2.745

10.  Minimizing attrition bias: a longitudinal study of depressive symptoms in an elderly cohort.

Authors:  Chung-Chou H Chang; Hsiao-Ching Yang; Gong Tang; Mary Ganguli
Journal:  Int Psychogeriatr       Date:  2009-03-17       Impact factor: 3.878

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.